Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/70081
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial
Author: Palmer, D.
Sullivan, T.
Gold, M.
Prescott, S.
Heddle, R.
Gibson, R.
Makrides, M.
Citation: British Medical Journal, 2012; 344(7845):E184-1-E184-11
Publisher: British Med Journal Publ Group
Issue Date: 2012
ISSN: 0959-535X
1756-1833
Statement of
Responsibility: 
D J Palmer, T Sullivan, M S Gold, S L Prescott, R Heddle, R A Gibson, M Makrides
Abstract: Objective: To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age. Design: Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial. Setting: Adelaide, South Australia. Participants: 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial. Interventions: The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks’ gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA. Main outcome measure: Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age. Results: No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06). Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen. Conclusion: n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower. Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood.
Keywords: Fetal Blood; Humans; Dermatitis, Atopic; Hypersensitivity, Immediate; Food Hypersensitivity; Fatty Acids, Omega-3; Fish Oils; Immunoglobulin E; Treatment Outcome; Regression Analysis; Breast Feeding; Pregnancy; Infant Formula; Dietary Supplements; Eggs; Infant; Australia; Female; Male; Maternal Nutritional Physiological Phenomena; Intention to Treat Analysis; Confounding Factors, Epidemiologic
Rights: © The Authors
RMID: 0020116380
DOI: 10.1136/bmj.e184
Grant ID: http://purl.org/au-research/grants/nhmrc/399389
Appears in Collections:Paediatrics publications

Files in This Item:
File Description SizeFormat 
hdl_70081.pdfPublished version368.92 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.